Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer
Akeso Takes a Significant Step in Cancer Treatment
In a groundbreaking move, Akeso, Inc. (HKEX: 9926.HK) has commenced a Phase I clinical trial of its first personalized mRNA vaccine, AK154. This trial aims to evaluate the vaccine's effectiveness as a standalone treatment and in combination with two bispecific antibodies, Cadonilimab and Ivonescimab, specifically for adjuvant treatment in patients who have undergone surgical removal of pancreatic cancer. This announcement marks a milestone not just for Akeso but for the field of cancer therapeutics, particularly in addressing the complexities of treating pancreatic cancer, known for its challenging prognosis.
Understanding AK154 and Its Potential
AK154 leverages Akeso's innovative mRNA technology, designed to create tailored therapeutic solutions based on individual patient profiles. This personalized neoantigen vaccine is generated by sequencing tumor tissue to identify mutations that can elicit a strong immune response. By targeting these immunogenic mutations, AK154 aims to convert the notoriously
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.